Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap2.62B
Enterprise Value1.49B
P/E Ratio-72.06
PEG Ratio0.31
Price/Sales Ratio1.49
Price/Book Ratio4.16
Enterprise/Revenue-0.33
Enterprise/EBITDA4.31

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.19
Operating Margin-0.21
AD

Management Effectiveness

Return On Assets-0.05
Return On Equity-0.06

Income Statement

Revenue685.8M
Revenue/Share0.64
Gross Profit616.49M
EBITDA-81.53M
Net Income-153.36M
Diluted EPS-0.14

Balance Sheet

Total Cash1.22B
Total Cash/Share1.18
Total Debt11.99M
Total Debt/Equity0.01
Current Ratio6.53
Book Value Per Share2.09

Price History

52-Week Change-32.73
52-Week High4.05
52-Week Low2.2
Moving Average 50 Days2.43
Moving Average 200 Days2.8

Statistics

Average Volume2.66M
Shares Outstanding340M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio-0.25
Last Split FactorN/A
Last Split DateN/A
AD